Table 1

Incidence of amenorrhea induced by the most commonly used chemotherapy regimens in breast cancer






Rate of amenorrhea






Reference
 Year
 Patients (n)
 Chemotherapy regimen
 Duration of treatment (months)
 Follow-up to definite amenorrhea (months)
 Percentage
 Age (years)
Goldhirsch and colleagues [4]
 1990
 541
 CMF
 1
 9
 14/34
 <40/>40


387
6
33/81
 <40/>40
Bines and colleagues [5]
 1996
 3,628
 CMF
 3 to 24
 12
 40/76
 <40/>40
Levine and colleagues [6]
 1998
 359
 CMF
 6
 NA
 42.6


132
 FEC
 6


Goodwin and colleagues [7]
 1999
 83
 CMF
 6
 12
 55.6


25
 FEC
 6
64.6
Nabholtz and colleagues [8]
 2002
 745
 ACD
 6
 33
 51.4


746
 FAC
 6


Fornier and colleagues [9]
 2005
 84
 AC-T/D
 6
 12
 13


82
 AC-T/D + tamoxifen

17
Martin and colleagues [10]
 2005
 420
 ACD
 6
 NA
 61.7


403
 FAC

52.4
Venturini and colleagues [11]
 2005
 503
 FEC
 4
 120
 64
Petrek and colleagues [12]
 2006
 120
 AC
 4
 36
 53


168
 ACT
 6
42


83
 CMF
 8
82


38
 FAC
 6
NA


34
 FACT
 6
NA


19
 ACD
 6
45
Tham and colleagues [13]
 2007
 75
 AC
 4
 12
 44/81
 <40/>40


116
 AC + T/D
 4 + 3
61/85
 <40/>40
Total
8,681




AC, adriamycin (doxorubicin), and cyclophosphamide; ACD, adriamycin (doxurubicin), cyclophosphamide and docetaxel; AC-T/D, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel)/docetaxel; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; FAC, 5-fluorouracil, adriamycin (doxorubicin), and cyclophosphamide; FACT, 5-fluorouracil, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel); FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; NA, not available.

Maltaris et al. Breast Cancer Research 2008 10:206   doi:10.1186/bcr1991